Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

Astria Therapeutics (NASDAQ:ATXS) has announced it will present initial Phase 1a trial data for STAR-0310, their long-acting OX40 receptor antagonist, at the upcoming EADV Congress 2025 in Paris.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/03/2025 - 08:00 AM

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology & Venereology (EADV) Congress 2025, taking place September 17-20, 2025 in Paris, France.

Stephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, will present initial results from the Phase 1a trial of STAR-0310 in healthy participants in a late-breaking oral presentation titled, “Demonstration of Early Proof-of-Concept for STAR-0310, a Long-Acting OX40 Receptor Antagonist: Initial Safety, PK, and PD Results from a Phase 1a Trial.” The presentation will take place at 2:15pm CEST on Wednesday, September 17^th in the Paris Nord room.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.